ID
IDXG.US Interpace Biosciences, Inc. Common stock
- Market cap
- USD 35.7M
- P/E
- 1.3x
- P/B
- 1.54x
- ROE
- 7.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is IDXG.US undervalued?
Graham numberThe Graham number of Interpace Biosciences, Inc. Common stock cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Interpace Biosciences, Inc. Common stock fundamental analysis
No fundamental analysis for Interpace Biosciences, Inc. Common stock yet.
Interpace Biosciences, Inc. Common stock stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Interpace Biosciences, Inc. Common stock
Interpace Biosciences, Inc. provides molecular diagnostic tests and pathology services for evaluating cancer risk in the United States. It offers ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. The company also provides ThyraMIR v2, which assesses thyroid nodules for malignancy risk using a proprietary microRNA gene expression classifier. It primarily serves physicians, cancer centers, clinics, laboratories, pathology groups, and hospitals. The …
Full company profileInterpace Biosciences, Inc. Common stock financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Interpace Biosciences, Inc. Common stock annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 13.1M | 15.9M | 21.9M | 24.2M | 32.4M | 41.3M | 31.8M | 40.0M | 46.9M | 38.7M | 36.3M |
| Gross Profit | 6.44M | 8.54M | 11.7M | 8.33M | 10.7M | 17.9M | 18.2M | 25.1M | 29.9M | 24.1M | 23.1M |
| Operating Income | -6.44M | -6.29M | -12.1M | -26.4M | -26.1M | -11.7M | -3.84M | 3.96M | 8.11M | 4.08M | 2.89M |
| EBITDA | - | -9.01M | -8.39M | -22.0M | -20.1M | -9.12M | -3.56M | 4.89M | 8.36M | 4.76M | 3.85M |
| Net Income | -8.33M | -12.2M | -12.2M | -26.7M | -26.5M | -14.9M | -22.0M | 1.95M | 6.70M | 24.6M | 1.76M |
| EPS | -3.83 | -4.39 | -4.25 | -68 | -6.52 | -3.56 | -5.11 | 0.45 | 7.60 | 28 | 0.32 |
| Balance Sheet | |||||||||||
| Total Assets | 41.8M | 53.6M | 48.4M | 51.5M | 45.7M | 38.4M | 16.0M | 13.0M | 14.8M | 33.8M | 34.5M |
| Total Liabilities | 35.2M | 13.7M | 15.5M | 29.8M | 28.2M | 34.3M | 79.1M | 74.7M | 17.0M | 11.5M | 11.3M |
| Shareholders' Equity | 6.53M | 39.9M | 32.9M | 21.7M | 17.5M | 4.12M | -63.1M | -61.7M | -2.22M | 22.4M | 23.2M |
| Cash & Short-term Investments | 602K | 15.2M | 6.07M | 2.32M | 3.37M | 3.06M | 4.83M | 3.50M | 1.46M | 2.51M | 2.69M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -8.94M | -15.3M | -8.67M | -19.0M | -14.0M | -8.72M | -7.69M | 3.79M | 4.65M | 5.83M | 762K |
| Capital Expenditure | 29.0K | 29.0K | 449K | 131K | 1.58M | 354K | 322K | 470K | 876K | 356K | 396K |
| Free Cash Flow | - | -15.3M | -9.12M | -19.1M | -15.6M | -9.07M | -7.69M | 3.32M | 3.77M | 5.48M | 366K |
| Ratios | |||||||||||
| ROE | -127.6% | -30.6% | -37.0% | -123.3% | -151.6% | -362.9% | - | - | - | 109.9% | 7.6% |
| ROA | -19.9% | -22.8% | -25.2% | -51.9% | -57.9% | -38.9% | -137.4% | 15.0% | 45.3% | 72.6% | 5.1% |
| Net Profit Margin | -63.7% | -76.8% | -55.7% | -110.4% | -81.6% | -36.2% | -69.0% | 4.9% | 14.3% | 63.5% | 4.8% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Interpace Biosciences, Inc. Common stock dividends
Interpace Biosciences, Inc. Common stock has not paid dividends in the last 9 fiscal years.
Last stock split: 1:5 on Aug 27, 2026.
Who owns Interpace Biosciences, Inc. Common stock
- Insiders 91.18%
- Institutions 0.00%
- Public & others 8.82%
- Shares outstanding 5.90M
- Free float 529K
Top funds holding IDXG.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| USAA Extended Market Index | 494.00 | 0.01% | -22.33% | Mar 2021 |
| NT Quality Small Cap Core | 22.00 | 0.00% | 0.00% | Mar 2021 |
| NT Quality SCC US Fund - L | 22.00 | 0.00% | 0.00% | Mar 2021 |
| NT Quality SCC Global Fund - NL | 2.00 | 0.00% | 0.00% | Dec 2020 |
| NT Quality SCC US Fund - NL | 2.00 | 0.00% | 0.00% | Dec 2020 |
Top institutions holding IDXG.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 117K | 2.85% | 0.00% | Dec 2020 |
| Geode Capital Management, LLC | 32.5K | 0.79% | 0.00% | Dec 2020 |
| Tower Research Capital LLC | 1.93K | 0.05% | 0.00% | Dec 2020 |
| Retirement Group, LLC | 1.00K | 0.02% | 0.00% | Mar 2021 |
| Advisor Group Holdings, Inc. | 50.00 | 0.00% | 0.00% | Dec 2020 |
| Wells Fargo & Co | 25.00 | 0.00% | 0.00% | Dec 2020 |
| Morgan Stanley - Brokerage Accounts | 3.00 | 0.00% | 0.00% | Dec 2020 |
| Hanson Mcclain Inc | 0.00 | 0.00% | -100.00% | Mar 2021 |
| Dimensional Fund Advisors, Inc. | 0.00 | 0.00% | -100.00% | Mar 2021 |
| UBS Group AG | 0.00 | 0.00% | -100.00% | Mar 2021 |
| Citadel Advisors Llc | 0.00 | 0.00% | -100.00% | Dec 2020 |
| Magnus Financial Group LLC | 0.00 | 0.00% | -100.00% | Dec 2020 |
| Penbrook Management LLC | 0.00 | 0.00% | -100.00% | Dec 2020 |
| Stonepine Capital Management Llc | 0.00 | 0.00% | -100.00% | Dec 2020 |
| Vanguard Group Inc | 0.00 | 0.00% | -100.00% | Mar 2021 |
| Glenmede Trust Co NA | 0.00 | 0.00% | -100.00% | Dec 2020 |
| Squarepoint Ops LLC | 0.00 | 0.00% | -100.00% | Mar 2021 |
Interpace Biosciences, Inc. Common stock company profile
- Company name
- Interpace Biosciences, Inc. Common stock
- Ticker
- IDXG.US
- Exchange
- USA Stocks
- Listed since
- May 20, 1998
- Sector
- Healthcare
- Industry
- Health Care Providers & Services
- Employees
- 102
- Fiscal year end
- December
- Address
- Waterview Plaza, Parsippany, NJ, United States, 07054
- Phone
- 855 776 6419
- Website
- interpace.com
About Interpace Biosciences, Inc. Common stock
Interpace Biosciences, Inc. provides molecular diagnostic tests and pathology services for evaluating cancer risk in the United States. It offers ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. The company also provides ThyraMIR v2, which assesses thyroid nodules for malignancy risk using a proprietary microRNA gene expression classifier. It primarily serves physicians, cancer centers, clinics, laboratories, pathology groups, and hospitals. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.
Interpace Biosciences, Inc. Common stock management
5- Dr. Thomas W. Burnell Ph.D.President, CEO & Chairman · born 1962
- Mr. Christopher McCarthyCFO & COO · born 1992
- Dr. Sydney D. Finkelstein M.D.Chief Pathology Officer
- Dr. Nicole Massoll M.D.Chief Medical Officer
- Mr. Patrick KaneVP & Corporate Controller